Abstract | BACKGROUND: METHODS: Neonates with gastrointestinal surgical conditions necessitating PN for ≥14 days and receiving MOLE ( SMOFlipid) from July 2016 to July 2019 were analyzed retrospectively. Unpaired and pair-matched historical surgical neonates treated with SOLE ( Intralipid) served as controls. The primary outcome measure was development of cholestasis (direct bilirubin ≥2 mg/dl). RESULTS: Overall, 63% (10 of 16) of MOLE patients and 22% (30 of 136) of SOLE patients developed cholestasis after ≥14 days of therapy (P = 0.005). The latency to developing cholestasis was significantly shorter in MOLE patients compared with SOLE patients. CONCLUSION: In surgical neonates, MOLE may not prevent cholestasis and should not be considered hepatoprotective. Regardless of ILE source, all surgical neonates should be closely monitored for development of IFALD. To date, there is still no ILE able to prevent IFALD.
|
Authors | Lumeng J Yu, Lorenzo Anez-Bustillos, Paul D Mitchell, Victoria H Ko, Jordan D Secor, Alexis P Hurley, Duy T Dao, Scott C Fligor, Bennet S Cho, Savas T Tsikis, Kathleen M Gura, Mark Puder |
Journal | JPEN. Journal of parenteral and enteral nutrition
(JPEN J Parenter Enteral Nutr)
Vol. 47
Issue 1
Pg. 30-40
(01 2023)
ISSN: 1941-2444 [Electronic] United States |
PMID | 36308408
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022 American Society for Parenteral and Enteral Nutrition. |
Chemical References |
- Fat Emulsions, Intravenous
- Soybean Oil
- Fish Oils
|
Topics |
- Infant
- Infant, Newborn
- Child
- Humans
- Fat Emulsions, Intravenous
- Soybean Oil
- Incidence
- Retrospective Studies
- Cholestasis
(etiology, therapy)
- Liver Diseases
(therapy)
- Intestinal Diseases
(therapy)
- Fish Oils
(therapeutic use)
- Liver Failure
(complications)
|